Therapeutic interleukin-2-antibody based fusion proteins
US5314995A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 22, 1990 |
| Grant date | May 24, 1994 |
| Priority date | — |
| Expiry date | Jan 22, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/80
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antibody-based fusion proteins wherein a portion of an immunoglobulin molecule is linked to a biologically active ligand. In particular embodiments of the invention, the fusion protein comprises a portion of an antibody which recognizes a cell surface antigen linked to a ligand which is a lymphokine or a cellular factor. A preferred embodiment of the fusion protein comprises the variable region of the anti-tumor monoclonal antibody L6 and an active lymphokine molecule such as IL-2. In another preferred embodiment of the present invention, the fusion protein comprises the variable region of the L6 monoclonal antibody and active platelet factor 4. The antibody-based fusion proteins of the invention may be used therapeutically to deliver biologically active ligands to a specific target cell or tissue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.